Literature DB >> 1467516

Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation.

M O Showers1, J F Moreau, D Linnekin, B Druker, A D D'Andrea.   

Abstract

The erythropoietin receptor (EPO-R) can be activated to signal cell growth by binding either EPO or gp55, the Friend spleen focus-forming virus (SFFV) glycoprotein. EPO binding induces tyrosine kinase activity and rapid tyrosine phosphorylation of several cellular substrates. To test for gp55-induced tyrosine kinase activity, we performed immunoblots on two murine cell lines that stably express EPO-R and gp55. Stimulation of the parental cell line, Ba/F3, with murine interleukin-3 (IL-3) resulted in rapid, dose-dependent tyrosine phosphorylation of a 97-Kd substrate. Stimulation with IL-3 or EPO of the Ba/F3 cells expressing the recombinant EPO-R (Ba/F3-EPO-R) resulted in tyrosine phosphorylation of the same p97 substrate. These latter cells, when transformed to growth factor-independence by the Friend gp55 glycoprotein, exhibited constitutive tyrosine phosphorylation of the 97-Kd substrate. Other growth factor-independent Ba/F3 subclones, transformed with either the oncoprotein, v-abl, or with a constitutively activated EPO-R, also had constitutive phosphorylation of a 97-Kd substrate. In CTLL-2-EPO-R cells, a T-lymphocyte line stably transfected with the EPO-R, the 97-Kd substrate was tyrosine-phosphorylated in response to IL-2 or EPO. The 97-Kd protein was constitutively phosphorylated in CTLL-2-EPO-R-gp55 cells. In conclusion, a 97-Kd protein found in two murine cell lines is tyrosine-phosphorylated in response to multiple growth factors and viral oncoproteins, and appears to be a central phosphoprotein in signal transduction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467516

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner.

Authors:  K Xia; N K Mukhopadhyay; R C Inhorn; D L Barber; P E Rose; R S Lee; R P Narsimhan; A D D'Andrea; J D Griffin; T M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

2.  Phosphorylation of erythropoietin receptors in the endoplasmic reticulum by pervanadate-mediated inhibition of tyrosine phosphatases.

Authors:  J Cohen; H Altaratz; Y Zick; U Klingmüller; D Neumann
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

3.  Erythropoietin and interleukin-2 activate distinct JAK kinase family members.

Authors:  D L Barber; A D D'Andrea
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

4.  Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development.

Authors:  Nick Carpino; William E Thierfelder; Ming-shi Chang; Chris Saris; Steven J Turner; Steven F Ziegler; James N Ihle
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

5.  A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation.

Authors:  D L Barber; J C DeMartino; M O Showers; A D D'Andrea
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

6.  Erythropoietin receptor signals both proliferation and erythroid-specific differentiation.

Authors:  E Liboi; M Carroll; A D D'Andrea; B Mathey-Prevot
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

7.  Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways.

Authors:  H Wakao; N Harada; T Kitamura; A L Mui; A Miyajima
Journal:  EMBO J       Date:  1995-06-01       Impact factor: 11.598

8.  Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO.

Authors:  Chantiya Chanswangphuwana; David S J Allan; Mala Chakraborty; Robert N Reger; Richard W Childs
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.